COLL vs GMAB: fair value comparison
Collegium Pharmaceutical, Inc. and Genmab A/S · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, COLL currently sits closer to the top of our discount ranking. GMAB carries the stronger quality grade.
| COLL | GMAB | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $35.58 | $28.68 |
| 12-month range | $31.78–$47.11 | $25.45–$33.27 |
| Sector rank | #42 of 113 Healthcare | #45 of 113 Healthcare |
| Quality grade | C- | A |
| Leverage | High | Low |
| Margin trend | — | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | — | Undervalued |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: COLL fair value analysis · GMAB fair value analysis